These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27198042)

  • 1. Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors.
    Pei Y; Xu Y; Ruan J; Rong L; Jiang M; Mo Y; Jiang X
    J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320316647240. PubMed ID: 27198042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.
    Tariq A; Mansoor MA; Marti HP; Jonsson G; Slettan A; Weeraman P; Apeland T
    Clin Biochem; 2018 Jun; 56():33-40. PubMed ID: 29655960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma gelsolin levels are decreased and correlate with fibrosis in IgA nephropathy.
    Han C; Zhang L; Zhu X; Tang J; Jin X
    Exp Biol Med (Maywood); 2013 Nov; 238(11):1318-27. PubMed ID: 24047794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multicenter investigation of therapeutic status of children with IgA nephropathy in China].
    Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):486-90. PubMed ID: 24267127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1.
    Tian J; Chen JH; Li Q; He Q; Lin WQ
    J Nephrol; 2005; 18(3):243-8. PubMed ID: 16013010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor.
    Oka K; Imai E; Moriyama T; Akagi Y; Ando A; Hori M; Okuyama A; Toki K; Kyo M; Kokado Y; Takahara S
    Nephrol Dial Transplant; 2000 May; 15(5):689-95. PubMed ID: 10809812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress in IgA nephropathy.
    Coppo R; Camilla R; Amore A; Peruzzi L
    Nephron Clin Pract; 2010; 116(3):c196-8, discussion c199. PubMed ID: 20606479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and outcome of IgA nephropathy in children from one single center experience.
    Mao Y; Zhou W; Zhou Z; Zhang C; Shen J; Yin L
    BMC Pediatr; 2023 Jul; 23(1):377. PubMed ID: 37495962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
    BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and damage induced by abnormal free radical reactions and IgA nephropathy.
    Chen JX; Zhou JF; Shen HC
    J Zhejiang Univ Sci B; 2005 Jan; 6(1):61-8. PubMed ID: 15593395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S; Söderberg MP; Berg UB
    Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
    Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
    QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.
    Cheng J; Zhang X; Tian J; Li Q; Chen J
    Int J Clin Pract; 2012 Oct; 66(10):917-23. PubMed ID: 22994326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.